EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
批准号:
8465828
负责人:
Brad Kahl
金额:
$49.69万
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-06-01 至 2015-02-28
关键词:
AffectBasic ScienceCancer BurdenCategoriesClinicalClinical ResearchClinical TrialsCommitComprehensive Cancer CenterData QualityEarly DiagnosisEastern Cooperative Oncology GroupEvaluationFacultyGrantHumanIndividualInstitutionLeadershipMalignant NeoplasmsOutcomeParticipantPatientsPopulationPreventionResearchSystemTranslational ResearchTranslationsUniversitiesWarWisconsinanticancer researchcancer carecancer therapydesignimprovedprograms
中文摘要
描述(由申请人提供):本申请为UW Paul P. Carbone综合癌症中心(UWCCC)的东部合作肿瘤小组(ECOG)的活动寻求支持。在过去的30年里,UWCCC在提供高质量数据和关键科学领导的同时,保持了模范的主要机构积累和强大的附属机构参与。机构评估一直将西澳大学ECOG项目在收益,行政和科学领导方面排名最高或接近最高。UWCCC的基础、转化和临床研究项目旨在通过改善癌症的预防、早期发现和治疗来减轻人们的癌症负担。UWCCC对癌症护理和研究的承诺从未如此坚定。在目前的拨款周期中,我们的临床空间增加了两倍,研究空间增加了一倍,这代表了近1亿美元的机构承诺,并将我们的癌症研究人员增加了近50%。UWCCC的教职员工将NCI合作小组视为抗癌战争的重要组成部分。将科学发现转化为人类群体和个体患者需要及时进行大规模临床试验的能力。ECOG提供了这个重要的论坛,UWCCC仍然高度致力于与ECOG的互利伙伴关系。
英文摘要
DESCRIPTION (provided by applicant): This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the UW Paul P. Carbone Comprehensive Cancer Center (UWCCC). Over the past 30 years, the UWCCC has maintained exemplary main institution accrual and strong affiliate participation while providing high quality data and key scientific leadership. Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative, and scientific leadership. The basic, translational, and clinical research programs of the UWCCC are designed to reduce the cancer burden on the population by improving prevention, early detection, and treatment of cancer. The UWCCC commitment to cancer care and research has never been stronger. During the current grant cycle, we have tripled our clinical space and doubled our research space, representing an institutional commitment of nearly $100 million, and increased our cancer focused faculty by nearly 50%. The UWCCC faculty views the NCI cooperative groups as essential components in the war on cancer. Translation of scientific discovery to human populations and to individual patients requires an ability to conduct large scale clinical trials in a timely fashion. ECOG provides this vital forum and the UWCCC remains highly committed to its mutually beneficial partnership with ECOG.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Potential role of polyribonucleotides in human neoplastic diseases.
多核糖核苷酸在人类肿瘤疾病中的潜在作用。
DOI:
--
发表时间:
1985
期刊:
Journal of biological response modifiers
影响因子:
--
作者:
[Borden,EC, Verma,AK, Wolberg,WH]
通讯作者:
Wolberg,WH
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
amonafide、caracemide 和高三尖杉酯碱治疗晚期肾细胞癌患者的 II 期试验。
DOI:
10.1007/bf00180819
发表时间:
1996
期刊:
Investigational new drugs
影响因子:
3.4
作者:
[Witte,RS, Hsieh,P, Elson,P, Oken,MM, Trump,DL]
通讯作者:
Trump,DL
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
阿霉素和紫杉醇加粒细胞集落刺激因子治疗转移性乳腺癌的 II 期试验:东部肿瘤合作组研究。
DOI:
10.1200/jco.1999.17.12.3828
发表时间:
1999
期刊:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子:
--
作者:
[Sparano,JA, Hu,P, Rao,RM, Falkson,CI, Wolff,AC, Wood,WC]
通讯作者:
Wood,WC
DOI:
10.1093/jnci/88.24.1828
发表时间:
1996-12
期刊:
Journal of the National Cancer Institute
影响因子:
--
作者:
[D. Tormey;R. Gray;H. Falkson]
通讯作者:
D. Tormey;R. Gray;H. Falkson
Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).
二溴调节醇、阿霉素、长春新碱、他莫昔芬和氟甲氨蝶呤联合甲氨蝶呤治疗转移性乳腺癌的诱导化疗:一项东部肿瘤合作组研究 (E1181)。
DOI:
10.1097/00000421-199802000-00023
发表时间:
1998
期刊:
American journal of clinical oncology
影响因子:
--
作者:
[Chang,AY, Putt,M, Pandya,KJ, Harris,J, Gelman,R, Tormey,DC, Falkson,G]
通讯作者:
Falkson,G
共 22 条
Phase I Study of Rituximab with L2-7001 (Aldesleukin) for Non-Hodgkin's Lymphoma
-
批准号:7043907
-
项目类别:
-
资助金额:$2.08万
-
财政年份:2003
-
负责人:Brad Kahl
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
-
批准号:7661563
-
项目类别:
-
资助金额:$62.1万
-
财政年份:1978
-
负责人:Brad Kahl
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
-
批准号:8284229
-
项目类别:
-
资助金额:$56.44万
-
财政年份:1978
-
负责人:Brad Kahl
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
-
批准号:7426841
-
项目类别:
-
资助金额:$61.06万
-
财政年份:1978
-
负责人:Brad Kahl
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
-
批准号:8079081
-
项目类别:
-
资助金额:$56.44万
-
财政年份:1978
-
负责人:Brad Kahl
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
-
批准号:7869601
-
项目类别:
-
资助金额:$61.48万
-
财政年份:1978
-
负责人:Brad Kahl
-
依托单位:
海外基金